PURPOSE: To assess the prevalence of hypotony in patients with severe forms of uveitis. METHODS: The Multicenter Uveitis Steroid Treatment (MUST) Trial, a randomized study, enrolled 255 patients. Patients with hypotony at the baseline visit were identified. RESULTS: Twenty (8.3%) of 240 patients with sufficient data had hypotony. Hypotony was more common in patients with uveitis ≥5 years duration (odds ratio [OR] = 5.0; p < .01), and in eyes with a history of ocular surgery (vitrectomy vs. none, OR = 3.1; p = .03). Hypotony was less in patients with older age of uveitis onset (>51 years vs. <51 years, OR = 0.1; p = .02), in Caucasian patients (OR = 0.1; p < .01) compared to African American patients. Hypotonous eyes were more likely to have visual impairment (OR = 22.9; p < .01). CONCLUSIONS:Hypotony is an important complication of uveitis and more commonly affects African-American patients, those with uveitis onset at a younger age, and those with longer disease duration. It is associated with visual impairment.
RCT Entities:
PURPOSE: To assess the prevalence of hypotony in patients with severe forms of uveitis. METHODS: The Multicenter UveitisSteroid Treatment (MUST) Trial, a randomized study, enrolled 255 patients. Patients with hypotony at the baseline visit were identified. RESULTS: Twenty (8.3%) of 240 patients with sufficient data had hypotony. Hypotony was more common in patients with uveitis ≥5 years duration (odds ratio [OR] = 5.0; p < .01), and in eyes with a history of ocular surgery (vitrectomy vs. none, OR = 3.1; p = .03). Hypotony was less in patients with older age of uveitis onset (>51 years vs. <51 years, OR = 0.1; p = .02), in Caucasian patients (OR = 0.1; p < .01) compared to African American patients. Hypotonous eyes were more likely to have visual impairment (OR = 22.9; p < .01). CONCLUSIONS:Hypotony is an important complication of uveitis and more commonly affects African-American patients, those with uveitis onset at a younger age, and those with longer disease duration. It is associated with visual impairment.
Authors: John D Sheppard; Melissa M Toyos; John H Kempen; Paramjit Kaur; C Stephen Foster Journal: Invest Ophthalmol Vis Sci Date: 2014-05-06 Impact factor: 4.799
Authors: Ana M Roldan; Nazlee Zebardast; Maxwell Pistilli; Naira Khachatryan; Abhishek Payal; Hosne Begum; Pichaporn Artornsombudh; Siddharth S Pujari; James T Rosenbaum; H Nida Sen; Eric B Suhler; Jennifer E Thorne; Nirali P Bhatt; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; Jeanine M Buchanich; John H Kempen Journal: Am J Ophthalmol Date: 2021-11-13 Impact factor: 5.258
Authors: Sheila T Angeles-Han; Courtney McCracken; Steven Yeh; Kirsten Jenkins; Daneka Stryker; Curtis Travers; Kelly Rouster-Stevens; Larry B Vogler; Scott R Lambert; Carolyn Drews-Botsch; Sampath Prahalad Journal: Am J Ophthalmol Date: 2015-08-06 Impact factor: 5.258
Authors: H Nida Sen; Francis M Abreu; Thomas A Louis; Elizabeth A Sugar; Michael M Altaweel; Susan G Elner; Janet T Holbrook; Douglas A Jabs; Rosa Y Kim; John H Kempen Journal: Ophthalmology Date: 2015-10-20 Impact factor: 12.079
Authors: John H Kempen; Michael M Altaweel; Janet T Holbrook; Elizabeth A Sugar; Jennifer E Thorne; Douglas A Jabs Journal: JAMA Date: 2017-05-16 Impact factor: 56.272